These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 20033380)

  • 1. PDGF and vessel maturation.
    Hellberg C; Ostman A; Heldin CH
    Recent Results Cancer Res; 2010; 180():103-14. PubMed ID: 20033380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
    Hasumi Y; Kłosowska-Wardega A; Furuhashi M; Ostman A; Heldin CH; Hellberg C
    Int J Cancer; 2007 Dec; 121(12):2606-14. PubMed ID: 17691110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for VEGF as a negative regulator of pericyte function and vessel maturation.
    Greenberg JI; Shields DJ; Barillas SG; Acevedo LM; Murphy E; Huang J; Scheppke L; Stockmann C; Johnson RS; Angle N; Cheresh DA
    Nature; 2008 Dec; 456(7223):809-13. PubMed ID: 18997771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization.
    Chaoran Z; Zhirong L; Gezhi X
    Graefes Arch Clin Exp Ophthalmol; 2011 Oct; 249(10):1493-501. PubMed ID: 21574021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment.
    Guo P; Hu B; Gu W; Xu L; Wang D; Huang HJ; Cavenee WK; Cheng SY
    Am J Pathol; 2003 Apr; 162(4):1083-93. PubMed ID: 12651601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms.
    Erber R; Thurnher A; Katsen AD; Groth G; Kerger H; Hammes HP; Menger MD; Ullrich A; Vajkoczy P
    FASEB J; 2004 Feb; 18(2):338-40. PubMed ID: 14657001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis inhibition in cancer therapy: platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) and their receptors: biological functions and role in malignancy.
    Appelmann I; Liersch R; Kessler T; Mesters RM; Berdel WE
    Recent Results Cancer Res; 2010; 180():51-81. PubMed ID: 20033378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular source and amount of vascular endothelial growth factor and platelet-derived growth factor in tumors determine response to angiogenesis inhibitors.
    Sennino B; Kuhnert F; Tabruyn SP; Mancuso MR; Hu-Lowe DD; Kuo CJ; McDonald DM
    Cancer Res; 2009 May; 69(10):4527-36. PubMed ID: 19401451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined VEGF and PDGF inhibition for neovascular AMD: anti-angiogenic properties of axitinib on human endothelial cells and pericytes in vitro.
    Siedlecki J; Wertheimer C; Wolf A; Liegl R; Priglinger C; Priglinger S; Eibl-Lindner K
    Graefes Arch Clin Exp Ophthalmol; 2017 May; 255(5):963-972. PubMed ID: 28161830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF.
    Benjamin LE; Hemo I; Keshet E
    Development; 1998 May; 125(9):1591-8. PubMed ID: 9521897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pericytes: a double-edged sword in cancer therapy.
    Meng MB; Zaorsky NG; Deng L; Wang HH; Chao J; Zhao LJ; Yuan ZY; Ping W
    Future Oncol; 2015; 11(1):169-79. PubMed ID: 25143028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excess vascular endothelial growth factor-A disrupts pericyte recruitment during blood vessel formation.
    Darden J; Payne LB; Zhao H; Chappell JC
    Angiogenesis; 2019 Feb; 22(1):167-183. PubMed ID: 30238211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delphinidin, a dietary anthocyanidin, inhibits platelet-derived growth factor ligand/receptor (PDGF/PDGFR) signaling.
    Lamy S; Beaulieu E; Labbé D; Bédard V; Moghrabi A; Barrette S; Gingras D; Béliveau R
    Carcinogenesis; 2008 May; 29(5):1033-41. PubMed ID: 18339683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
    Bergers G; Song S; Meyer-Morse N; Bergsland E; Hanahan D
    J Clin Invest; 2003 May; 111(9):1287-95. PubMed ID: 12727920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions.
    Yamagishi S; Yonekura H; Yamamoto Y; Fujimori H; Sakurai S; Tanaka N; Yamamoto H
    Lab Invest; 1999 Apr; 79(4):501-9. PubMed ID: 10212003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension.
    Ricard N; Tu L; Le Hiress M; Huertas A; Phan C; Thuillet R; Sattler C; Fadel E; Seferian A; Montani D; Dorfmüller P; Humbert M; Guignabert C
    Circulation; 2014 Apr; 129(15):1586-97. PubMed ID: 24481949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of pericytes in vascular morphogenesis.
    Betsholtz C; Lindblom P; Gerhardt H
    EXS; 2005; (94):115-25. PubMed ID: 15617474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis.
    Goede V; Schmidt T; Kimmina S; Kozian D; Augustin HG
    Lab Invest; 1998 Nov; 78(11):1385-94. PubMed ID: 9840613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
    Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
    Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.